Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post on LinkedIn:
“The RICE study.
Finally, some data – even though retrospective and just 39 patients – on one of the hottest unanswered questions in gynecologic oncology: can we safely and effectively rechallenge immune checkpoint inhibitors?
The RICE study, the largest multicentre retrospective series to date evaluating IO rechallenge in recurrent/metastatic cervical and endometrial cancers, provides encouraging real-world evidence.
Title: Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: A multi-center retrospective study – RICE study
Authors: Rayan Kabirian, Mathilde De Saint Ghislain, Olivia Le Saux, Laurent Mathiot, Jean-Sébastien Frenel, Paule Augereau, Alexandra Forestier, Jean David Fumet, Lauriane Eberst, Stanislas Quesada, Louise Mbengue, Elsa Kalbacher, Céline Lescure, Thibault De La Motte Rouge, Juan Francisco Grau Bejar, Solenn Barraud, Thomas Genevee, Diana Bello, Manuel Rodrigues, Alexandra Leary
Read The Full Article
Among patients rechallenged after disease progression:
- Objective response rate of 52% (vs 76% during the initial ICI exposure)
- Median PFS of 6 months, demonstrating clinically meaningful activity even after prior immunotherapy
- Manageable safety profile, with only 13% discontinuing rechallenge because of immune-related toxicity, substantially lower than during the initial ICI course
Congratulations to the investigators for tackling such a clinically relevant and timely question.”